Oncotelic subsidiary Sapu Nano to present everolimus tissue-toxicity data at SOT 2026

Oncotelic Therapeutics, Inc.

Sapu Nano (Oncotelic minority interest) to present everolimus toxicology poster at SOT 2026 in San Diego on Mar 23.
Presentation (#3539, board K692) focuses on tissue concentration-driven effects beyond traditional plasma pharmacokinetics.
Data aims to inform improved delivery strategies for mTOR inhibitors, including IV and nanoparticle formulations.
Oncotelic (OTLC) holds minority stake in Sapu Nano; no financial terms or guidance provided.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.